GlassScriptPhysician profile
Daniel O'Connor
NPI 1184398026
$2,597.14
in general payments reported to CMS, 2019-2025
20 companies · $816 in 2025
The $816 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $198 · 2023: $380 · 2024: $1,203 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.04 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $466.92 | 2024-2025 | |
| Alcon Vision LLC | $422.33 | 2022-2025 | Clareon, Rocklatan, Tryptyr |
| Regeneron Healthcare Solutions, INC. | $266.57 | 2023-2025 | Eylea Hd, Dupixent, Eylea |
| Bausch & Lomb Americas INC. | $251.25 | 2022-2025 | Xiidra, Envista Mx60 Iol |
| Apellis Pharmaceuticals, INC. | $227.14 | 2024-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $175.76 | 2024-2025 | Acthar |
| Genentech USA, INC. | $160.76 | 2024-2025 | Vabysmo |
| Dompe US, INC. | $115.67 | 2024-2025 | Oxervate |
| Coopervision INC. | $86.50 | 2023 | Myday Contact Lens |
| Astellas Pharma US INC | $80.98 | 2023-2025 | Izervay |
| Oyster Point Pharma, INC. | $76.50 | 2023-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $55.44 | 2025 | Xdemvy |
| Coherus Oncology, INC. | $42.16 | 2023 | |
| Ani Pharmaceuticals, INC. | $31.76 | 2025 | Iluvien |
| Rayner Intraocular Lenses Limited | $29.40 | 2024 | Rayone Spheric, Omidria, Rayone Emv |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $28.62 | 2024-2025 | Idose, Idosetr |
| Novartis Pharmaceuticals Corporation | $26.47 | 2022 | |
| Thea Pharma INC. | $19.23 | 2025 | Iyuzeh |
| New World Medical,INC. | $18.06 | 2025 | Via360, Kahook Dual Blade, Streamline |
| Biotissue Holdings INC. | $15.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel O'Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.